Investment
Features
FeesSafety
Academy
More
Pluang+

Circle secures USDC as Chelsea FC's front shirt sponsor from 2026/27, a Premier League crypto first.

Market News
28 Aug 2026
Blockonomi
View Source
Bullish
Circle secures USDC as Chelsea FC's front shirt sponsor from 2026/27, a Premier League crypto first.

Circle Internet Group has become the first cryptocurrency financial services company to secure the principal front-of-shirt sponsorship for a Premier League club, Chelsea FC, starting in the 2026/27 season. The USDC stablecoin logo will appear on Chelsea’s Men’s, Women’s, and Academy kits, marking a significant milestone in football's digital evolution. Chelsea sought around £65 million annually for the sponsorship, though exact financial terms remain undisclosed. Circle's FCA authorization ensures regulatory compliance, setting it apart from other crypto firms with Premier League partnerships limited to sleeve ads. The new kits will debut this Sunday at Stamford Bridge against Brighton.

More News

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...

Others
Neutral
42 minutes ago
EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...

Company Fundamentals
Neutral
42 minutes ago
Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

Market News
Bullish
42 minutes ago
Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...

Company Fundamentals
Bullish
42 minutes ago
JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Market News
Bullish
42 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App